Protective Immunity Evoked Against Anthrax Lethal Toxin after a Single Intramuscular Administration of an Adenovirus-Based Vaccine Encoding Humanized Protective Antigen

Yadi Tan, Neil R. Hackett, Julie L. Boyer, Ronald Crystal

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Because of the need to develop a vaccine to rapidly protect the civilian population in response to a bioterrorism attack with Bacillus anthracis, we designed AdsechPA, a replication-deficient human serotype 5 adenovirus encoding B. anthracis protective antigen (PA) with codons optimized for expression in mammalian cells. With a single intramuscular administration to mice of 109 particle units of AdsechPA, a dose that can be scaled to human use, anti-PA antibodies were evoked more rapidly and at a higher level than with a single administration of the new U.S. military recombinant PA/Alhydrogel vaccine. Importantly, AdsechPA afforded approximately 2.7-fold more protection than the recombinant PA vaccine against B. anthracis lethal toxin challenge 4 weeks after a single vaccination. Even at 11 days postvaccination, AdsechPA provided some survival benefit, whereas the rPA/Alhydrogel vaccine provided none. In the context that equivalent human doses of Ad vectors have already been demonstrated to be safe in humans, a single administration of AdsechPA may provide the means to rapidly protect the civilian population against B. anthracis in response to a bioterrorism attack.

Original languageEnglish
Pages (from-to)1673-1682
Number of pages10
JournalHuman Gene Therapy
Volume14
Issue number17
DOIs
Publication statusPublished - 20 Nov 2003
Externally publishedYes

Fingerprint

Adenovirus Vaccines
Immunity
Vaccines
Bioterrorism
Aluminum Hydroxide
Antigens
Bacillus anthracis
Adenoviridae
Codon
Population
Vaccination
Survival
anthrax toxin
Antibodies

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Protective Immunity Evoked Against Anthrax Lethal Toxin after a Single Intramuscular Administration of an Adenovirus-Based Vaccine Encoding Humanized Protective Antigen. / Tan, Yadi; Hackett, Neil R.; Boyer, Julie L.; Crystal, Ronald.

In: Human Gene Therapy, Vol. 14, No. 17, 20.11.2003, p. 1673-1682.

Research output: Contribution to journalArticle

@article{258c6911218b4c879ff5911753a65d74,
title = "Protective Immunity Evoked Against Anthrax Lethal Toxin after a Single Intramuscular Administration of an Adenovirus-Based Vaccine Encoding Humanized Protective Antigen",
abstract = "Because of the need to develop a vaccine to rapidly protect the civilian population in response to a bioterrorism attack with Bacillus anthracis, we designed AdsechPA, a replication-deficient human serotype 5 adenovirus encoding B. anthracis protective antigen (PA) with codons optimized for expression in mammalian cells. With a single intramuscular administration to mice of 109 particle units of AdsechPA, a dose that can be scaled to human use, anti-PA antibodies were evoked more rapidly and at a higher level than with a single administration of the new U.S. military recombinant PA/Alhydrogel vaccine. Importantly, AdsechPA afforded approximately 2.7-fold more protection than the recombinant PA vaccine against B. anthracis lethal toxin challenge 4 weeks after a single vaccination. Even at 11 days postvaccination, AdsechPA provided some survival benefit, whereas the rPA/Alhydrogel vaccine provided none. In the context that equivalent human doses of Ad vectors have already been demonstrated to be safe in humans, a single administration of AdsechPA may provide the means to rapidly protect the civilian population against B. anthracis in response to a bioterrorism attack.",
author = "Yadi Tan and Hackett, {Neil R.} and Boyer, {Julie L.} and Ronald Crystal",
year = "2003",
month = "11",
day = "20",
doi = "10.1089/104303403322542310",
language = "English",
volume = "14",
pages = "1673--1682",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "17",

}

TY - JOUR

T1 - Protective Immunity Evoked Against Anthrax Lethal Toxin after a Single Intramuscular Administration of an Adenovirus-Based Vaccine Encoding Humanized Protective Antigen

AU - Tan, Yadi

AU - Hackett, Neil R.

AU - Boyer, Julie L.

AU - Crystal, Ronald

PY - 2003/11/20

Y1 - 2003/11/20

N2 - Because of the need to develop a vaccine to rapidly protect the civilian population in response to a bioterrorism attack with Bacillus anthracis, we designed AdsechPA, a replication-deficient human serotype 5 adenovirus encoding B. anthracis protective antigen (PA) with codons optimized for expression in mammalian cells. With a single intramuscular administration to mice of 109 particle units of AdsechPA, a dose that can be scaled to human use, anti-PA antibodies were evoked more rapidly and at a higher level than with a single administration of the new U.S. military recombinant PA/Alhydrogel vaccine. Importantly, AdsechPA afforded approximately 2.7-fold more protection than the recombinant PA vaccine against B. anthracis lethal toxin challenge 4 weeks after a single vaccination. Even at 11 days postvaccination, AdsechPA provided some survival benefit, whereas the rPA/Alhydrogel vaccine provided none. In the context that equivalent human doses of Ad vectors have already been demonstrated to be safe in humans, a single administration of AdsechPA may provide the means to rapidly protect the civilian population against B. anthracis in response to a bioterrorism attack.

AB - Because of the need to develop a vaccine to rapidly protect the civilian population in response to a bioterrorism attack with Bacillus anthracis, we designed AdsechPA, a replication-deficient human serotype 5 adenovirus encoding B. anthracis protective antigen (PA) with codons optimized for expression in mammalian cells. With a single intramuscular administration to mice of 109 particle units of AdsechPA, a dose that can be scaled to human use, anti-PA antibodies were evoked more rapidly and at a higher level than with a single administration of the new U.S. military recombinant PA/Alhydrogel vaccine. Importantly, AdsechPA afforded approximately 2.7-fold more protection than the recombinant PA vaccine against B. anthracis lethal toxin challenge 4 weeks after a single vaccination. Even at 11 days postvaccination, AdsechPA provided some survival benefit, whereas the rPA/Alhydrogel vaccine provided none. In the context that equivalent human doses of Ad vectors have already been demonstrated to be safe in humans, a single administration of AdsechPA may provide the means to rapidly protect the civilian population against B. anthracis in response to a bioterrorism attack.

UR - http://www.scopus.com/inward/record.url?scp=0344442277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344442277&partnerID=8YFLogxK

U2 - 10.1089/104303403322542310

DO - 10.1089/104303403322542310

M3 - Article

VL - 14

SP - 1673

EP - 1682

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 17

ER -